Learn more on this topic: Nuances in the Management of Aggressive Lymphomas

How does genetic information affect treatment decisions in aggressive lymphoma, such as DLBCL?

Paul Hamlin, MD
Memorial Sloan Kettering Cancer Center

Related Material

What are the unique side effects associated with venetoclax?

What is the role of immunotherapy in aggressive lymphoma? What do APs need to know about managing immune-related adverse events in patients?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.